NAD chastises Natrol for claims about Promensil
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday recommended that Natrol, which distributes Promensil, a dietary supplement marketed for the relief of the symptoms of menopause, modify or discontinue certain claims for the supplement. NAD did find, however, that the advertiser had provided adequate support for certain claims.
At the outset of the NAD inquiry, Natrol explained that Promensil is a brand of dietary supplement for the relief of menopausal symptoms. The supplement contains an extract of red clover, standardized to provide four naturally occurring isoflavones, biochanin A, formononetin, genistein and daidzein.
Following a review of each of the 22 cited studies, NAD found that while there is significant research that Promensil may provide certain benefits for menopausal women, the challenged advertising overstates the results of such research.
Specifically, NAD determined that there was insufficient evidence to support the message conveyed by the advertiser’s claim that “22 clinical studies can’t be wrong.” NAD determined, as well, that because of conflicting efficacy research, as well as deficiencies in many of the studies, the evidence was not sufficiently reliable to support the advertiser’s unqualified “clinically proven” claims and recommended that such claims be discontinued or modified.
NAD further recommended that the advertiser’s “Doctor Recommended” claim be modified to clearly and conspicuously disclose that the doctors surveyed were Australian and Canadian.
With respect to claims concerning hot flashes, NAD found that, based on the current research, the advertiser can make qualified claims that more accurately reflect the current state of the science, i.e., that Promensil may help reduce the frequency and/or the severity of hot flashes.
NAD also found that Natrol provided a reasonable basis to make certain limited claims that Promensil can help relieve the frequency and/or severity of hot flashes, increase testosterone which may alleviate certain mood swings, promote breast health, promote heart health and promote emotional well-being.
Natrol noted in its advertiser’s statement that it would modify its advertising to conform to NAD’s findings, the NAD reported. “Natrol thanks the NAD for its consideration and review of the evidence submitted to it by Natrol. Although Natrol respectfully disagrees with the decision reached by the NAD, it voluntarily accepts the NAD’s recommendations and suggestions on the claims in question,” the company stated in its letter to NAD.
Thank you, NAD, for this (2007) report on Promensil. I have just purchased this product on the recommendation of my pharmacist. Obviously, the company took your recommendations to heart and re-worded it's claims. However, I must say, in my case, that is, that the product seems to be living up to its promises/statements. I have been suffering from severe menopausal symptoms for the last six years; it's been horrible living like I have been. But, since starting the Promensil six days ago I have noticed a significant decrease in the number of hot flashes I usually have throughout the day. The severity (thank you, Jesus) of the heat and sweating is GREATLY reduced. :) So, I want to thank you for looking out for consumers and your fair reporting, and a big thank you to Natrol for putting out this great product!
Wolfgram testifies to Senate on behalf of NACDS
WASHINGTON Peter Wolfgram, president and chief executive officer of Bungalow Drug, testified today in front of the Senate Committee on Finance regarding the role of community pharmacy in the solution to methamphetamine production.
Speaking on behalf of the National Association of Chain Drug Stores, Wolfgram expressed his concerns before the committee as a representative of the 39,000 pharmacies and almost 1,000 suppliers of products and services to the chain drug industry that are included in NACDS’ membership. He addressed the problems of methamphetamine production and the steps taken by pharmacies to curb domestic production. He urged the committee to take appropriate measures to stem the flow of methamphetamine from abroad, and pledged that NACDS will continue working with Congress to help curb the illicit use and production of methamphetamine.
Bungalow Drug is a family-owned, hometown pharmacy chain based in Belgrade, Montana. The company provides pharmacy services for approximately 3,000 patients out of three locations in Montana with 24 employees including eight full- and part-time pharmacists. “Mr. Wolfgram brings a vast amount of chain drug experience to the table and we are pleased to have him testify on our behalf to address the proactive role of community pharmacy as part of the solution to drug abuse,” stated NACDS president and chief executive officer, Steve Anderson.
While the Combat Methamphetamine Epidemic Act or “Combat Meth Act” created a national standard for retailers to follow in order to limit access to methamphetamine precursors, and significantly reduced domestic methamphetamine production, the foreign supply is increasing as those addicted search out alternative sources of methamphetamine outside U.S. borders.
Even before the law was implemented, pharmacists had been taking proactive steps to reduce the theft and illegitimate use of products containing pseudoephedrine and ephedrine, including restricting sales, placing these products behind pharmacy and/or sales counters and participating in other drug-awareness activities.
“Chain drug stores will continue to advocate for policies and practices that will be truly effective in cutting off the methamphetamine supply chain and addressing other drug abuse issues in a way that does not limit the legitimate sale and use of medication that patients rely on,” said Anderson. “We applaud Finance Committee Chairman Max Baucus [D-Mont.] for his commitment to combating illegal drug manufacturing and abuse, and for listening to those, like community pharmacy personnel, who live out their commitment to this cause every day.”
No comments found
Bayer introduces two wireless blood glucose meters in Europe
TARRYTOWN, N.Y. Bayer Healthcare on Monday announced in Europe the introduction of two new wireless blood glucose meters, the results of which will be able to be transmitted wirelessly to the patients’ insulin pump or the hospital’s central data processing system.
“The addition of these two wireless meters—Contour Pro and Contour Link—to our business has given us a new strategic focus,” stated Dr. Roberto Parotelli, head of the European Diabetes Care Division of Bayer HealthCare. “Their complimentary features will make a significant contribution to improving safety for people with diabetes.”
The new systems will be launched in selected markets in various European countries in the coming months, the company announced.
No comments found